Document MobeQG5MvBRjBnYaOKGqa0o8z

Corporate Health Physics Corporate Industrial Hygiene & Ergonomics Corporate Occupational Medicine Corporate Toxicology 3M Medical Department 3M Center, Building 220-2E-02 PO Box 33220 ' - ' St. Paul, MN 55133-3220 651 733 1110 May 3,2000 Facsimile Dr. Jennifer Seed 202-260-1279 USEPA Headquarters Ariel Rios Building 1200 Pennsylvania Avenue, N. W. Washington, DC 20460 Re: Serum measurements for Argus Studies 418-013 (through lactation) and 418-015 (during gesatation) Dear Jennifer: I am including in this fax the two sets of serum perfluorooctanesulfonate measurements from the following two studies: 1. Oral (Gavage) Pharmacokinetic Recovery Study of PFOS in Rats, Argus Laboratories Protocol No. 418-015, 3M Reference No. T-6295.14, AdvancedBioanalytical Services Study No. FACT-TOX-111. 2. Oral (Gavage) Pharmacokinetic Study of PFOS in Rats, Argus Laboratories Protocol No. 418-013, 3M Reference No. T-6295.12, Advanced Bioanalytical Services Study No. FACT-TOX-110. The informnation which I have included relates to the analytical studies indicated above in bold italics. Included are pages 10-19 of FACT-TOX-111 and pages 13-23 of FACT-TOX-110. 3M has previously sent the in-life reports and protocols for the analytical phase to the attention of Dr. Hernandez. I would be happy to meet with you and your EPA colleagues and consultants to provide whatever assistance you may desire in understanding the toxicological information that is being provided. Please contact me with any questions or if you would like to arrange a meeting. Sincerely, John L. Butenhoff, Ph.D., CIH, DABT Senior Laboratory Manager Corporate Toxicology (651)733-1962